Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

601 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: ATLANTIC-Morphine.
Lapostolle F, Van't Hof AW, Hamm CW, Stibbe O, Ecollan P, Collet JP, Silvain J, Lassen JF, Heutz WMJM, Bolognese L, Cantor WJ, Cequier A, Chettibi M, Goodman SG, Hammett CJ, Huber K, Janzon M, Merkely B, Storey RF, Ten Berg J, Zeymer U, Licour M, Tsatsaris A, Montalescot G; ATLANTIC Investigators. Lapostolle F, et al. Among authors: ten berg j. Am J Cardiovasc Drugs. 2019 Apr;19(2):173-183. doi: 10.1007/s40256-018-0305-0. Am J Cardiovasc Drugs. 2019. PMID: 30353444 Clinical Trial.
Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction.
Heestermans AA, Van Werkum JW, Hamm C, Dill T, Gosselink AT, De Boer MJ, Van Houwelingen G, Hoorntje JC, Koopmans PC, Ten Berg JM, Van 't Hof AW. Heestermans AA, et al. Among authors: ten berg jm. J Thromb Haemost. 2009 Oct;7(10):1612-8. doi: 10.1111/j.1538-7836.2009.03573.x. Epub 2009 Aug 11. J Thromb Haemost. 2009. PMID: 19682233 Free article. Clinical Trial.
Acute and subacute stent thrombosis after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: incidence, predictors and clinical outcome.
Heestermans AA, van Werkum JW, Zwart B, van der Heyden JA, Kelder JC, Breet NJ, van't Hof AW, Dambrink JH, Koolen JJ, Brueren BR, Zijlstra F, ten Berg JM. Heestermans AA, et al. Among authors: ten berg jm. J Thromb Haemost. 2010 Nov;8(11):2385-93. doi: 10.1111/j.1538-7836.2010.04046.x. J Thromb Haemost. 2010. PMID: 20831622 Free article.
High-dose tirofiban pretreatment reduces the need for bail-out study medication in patients with ST-segment elevation myocardial infarction: results of a subgroup analysis of the On-TIME 2 trial.
Hermanides RS, Heestermans AA, Ten Berg JM, Gosselink AT, Ottervanger JP, van Houwelingen KG, Kolkman JJ, Stella PR, Dill T, Hamm C, van 't Hof AW. Hermanides RS, et al. Among authors: ten berg jm. Heart. 2011 Jan;97(2):106-11. doi: 10.1136/hrt.2010.194951. Epub 2010 Oct 20. Heart. 2011. PMID: 20962338 Clinical Trial.
A comparison between upfront high-dose tirofiban versus provisional use in the real-world of non-selected STEMI patients undergoing primary PCI: Insights from the Zwolle acute myocardial infarction registry.
Heestermans AA, Hermanides RS, Gosselink AT, de Boer MJ, Hoorntje JC, Suryapranata H, Ottervanger JP, Dambrink JH, Kolkman E, Ten Berg JM, Zijlstra F, van 't Hof AW. Heestermans AA, et al. Among authors: ten berg jm. Neth Heart J. 2010 Dec;18(12):592-7. doi: 10.1007/s12471-010-0840-z. Neth Heart J. 2010. PMID: 21301621 Free PMC article.
A comparison of prasugrel at the time of percutaneous coronary intervention or as pretreatment at the time of diagnosis in patients with non-ST-segment elevation myocardial infarction: design and rationale for the ACCOAST study.
Montalescot G, Bolognese L, Dudek D, Goldstein P, Hamm C, Tanguay JF, ten Berg J, Widimsky P, Luo J, Miller DL, Goedicke J. Montalescot G, et al. Among authors: ten berg j. Am Heart J. 2011 Apr;161(4):650-656.e1. doi: 10.1016/j.ahj.2010.10.017. Epub 2011 Feb 25. Am Heart J. 2011. PMID: 21473962 Clinical Trial.
Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial.
Newby LK, Marber MS, Melloni C, Sarov-Blat L, Aberle LH, Aylward PE, Cai G, de Winter RJ, Hamm CW, Heitner JF, Kim R, Lerman A, Patel MR, Tanguay JF, Lepore JJ, Al-Khalidi HR, Sprecher DL, Granger CB; SOLSTICE Investigators. Newby LK, et al. Lancet. 2014 Sep 27;384(9949):1187-95. doi: 10.1016/S0140-6736(14)60417-7. Epub 2014 Jun 12. Lancet. 2014. PMID: 24930728 Clinical Trial.
601 results